Publication: Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand
Issued Date
2004-06-01
Resource Type
ISSN
08892229
Other identifier(s)
2-s2.0-3042681156
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
AIDS Research and Human Retroviruses. Vol.20, No.6 (2004), 642-644
Suggested Citation
Wannee Kantakamalakul, Mark De Souza, Chitraporn Karnasuta, Arthur Brown, Sanjay Gurunathan, Deborah Birx, Prasert Thongcharoen, The Taveg Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand. AIDS Research and Human Retroviruses. Vol.20, No.6 (2004), 642-644. doi:10.1089/0889222041217473 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/21384
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand
Abstract
A phase I/II prime-boost vaccine trial in HIV-1-seronegative adults was conducted in Thailand using ALVAC-HIV (vCP1521) as a prime, boosting with either oligomeric gp160 TH023/LAI or Chiron HIV Thai subtype E (CM235) plus U.S. subtype B (SF2) gp120. Cytotoxic T lymphocyte (CTL) assays were conducted at one of the vaccine trial sites (Siriraj Hospital) at a single time point following the completion of immunization demonstrated that 8 of 50 (16%) vaccine recipients showed HIV-specific CTL by standard chromium release assay (CRA) after in vitro stimulation (IVS) for 2 weeks. Five additional vaccinees (13/50 = 26%) showed CTL responses after IVS for up to 4 weeks. Moreover, one volunteer with a positive CTL response to a single HIV antigen at Day 14 demonstrated a response to an additional HIV-1 antigen(s) after the longer IVS period. CTL activity was CD8+ restricted. Despite extension of the IVS up to 4 weeks, no CTL responses were detected in placebo recipients. These results imply that extension of the IVS period may increase the sensitivity of the CRA when measuring HIV-specific CTL in ALVAC-HIV prime-boost recipients without compromising specificity.
